Cubicin News
Most Popular Cubicin Story
ALSO NOTED: Alexza gains $50M; AstraZeneca, Cubist sign $10.25M licensing pact; and much more...
> Symphony Capital Partners will provide $50 million to Alexza Pharmaceuticals for the development of AZ-002 and AZ-004, both of which are in Phase II trials. Release
> Shanghai-based Cathay Industrial Biotech has closed a $52 million second round of financing. Investors include Goldman Sachs, Gramineae Holdings Company Limited, GM Investment Company Limited and New Horizon Evergreen Investment. …
... Read more...Latest Headlines
- June 27, 2005
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
